Decades of studies have conclusively demonstrated that smoking combustible cigarettes, as well as second-hand smoke, are major causes of global morbidity and mortality from a constellation of conditions, including but not limited to chronic disorders such as pulmonary and cardiovascular disease, and multiple types of cancer. The most effective approach to harm reduction is smoking cessation. However, the addictive nature of nicotine and the behavioral aspects of smoking make this a challenging process. There is therefore a significant need to develop and regulate products such as e-cigarettes, that could potentially serve as reduced-risk alternatives. In this paper, we provide background on clinical studies in the US for new tobacco products and delineate how the appropriate testing facilities, equipment, and experienced staff are essential to generating high-quality data.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
In this infographic, we share the emerging technologies beyond monoclonal antibodies and the bioanalytical methods to support the new technologies.
With over 20 years of experience in execution of comprehensive Phase I-IIa studies, Frontage Clinical Services has full capabilities to conduct a broad range of study types (e.g. PK, confinement and ambulatory) in support of tobacco related studies. With extensive expertise in a wide variety of delivery systems, we are well-positioned to conduct tobacco-focused clinical research studies.
In this study, we quantify Neurofilament Light Chain (NF-L) in human plasma, serum, and CSF on the Quanterix Simoa™ Platform using a commercial Simoa NF-Light Assay Kit provided by Quanterix Corporation. We also discuss potential applications.